| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Chitosan — Chitosan is a deacetylated chitin-derived cationic polysaccharide used as a biocompatible biomaterial, immune-active adjuvant, and multifunctional delivery polymer rather than a standard standalone cytotoxic anticancer drug. Its formal classification is a natural polymeric biomaterial and drug-delivery excipient/platform. Standard abbreviations include CS; related derivatives include chitooligosaccharides and glycated chitosan in some oncology contexts. It is typically sourced from crustacean shells, though fungal sources also exist. In cancer research, its importance is driven mainly by mucoadhesion, protonatable amines, cargo complexation, endosomal interaction, and formulation-tunable immune and tumor-microenvironment effects; biological behavior depends strongly on molecular weight, degree of deacetylation, pattern of substitution, and formulation architecture. Low–molecular weight chitosan and modified forms have also been reported to inhibit angiogenesis, modulate tumor microenvironment acidity, interfere with metastasis, and induce apoptosis in some in vitro systems. A major translational role of chitosan is as a nanoparticle carrier for chemotherapeutics, genes, and immunotherapies, improving stability and targeted delivery. Effects vary significantly depending on molecular weight, degree of deacetylation, and formulation. Primary mechanisms (ranked): Chitosan has been shown to inhibit the growth of various types of cancer cells, including breast, lung, and colon cancer cells.Chitosan has been shown to inhibit angiogenesis, stimulate the immune system, and anti-inflammatory. Chitosan is only soluble in acidic settings, hence limiting its use in neutral or alkaline pH circumstances
Bioavailability / PK relevance: Chitosan is not a conventional systemically bioavailable small molecule. Native CS has limited neutral-pH solubility and its translational behavior is dominated by route, particle size, surface chemistry, molecular weight, and degree of deacetylation. Oncology relevance is strongest in local, mucosal, intratumoral, hydrogel, nanoparticle, and carrier-based applications rather than free systemic exposure. In-vitro vs systemic exposure relevance: Many direct in-vitro anticancer studies use concentrations, contact conditions, or modified chitosan constructs that are not straightforwardly comparable to achievable systemic exposure of native CS. Therefore, carrier/platform effects and local-delivery applications are more clinically plausible than relying on native chitosan as a systemic concentration-driven anticancer agent. Clinical evidence status: Predominantly preclinical for direct anticancer use. Human oncology evidence is limited and mostly adjunctive, formulation-specific, or device/supportive-care related. There is no established regulatory status for chitosan as a standalone approved anticancer drug, although chitosan-containing or chitosan-derived oncology platforms and local immunotherapy approaches have entered early clinical investigation. Mechanistic pathway table
|
| Source: |
| Type: |
| Tumor Microenvironment: Cancer cells often thrive in a more acidic environment compared to normal cells. This is partly due to the metabolic processes of cancer cells, which can produce lactic acid and other acidic byproducts. The acidic microenvironment can promote tumor growth and invasion. Many tumors exhibit an acidic microenvironment. This is largely due to the high rate of glycolysis (often referred to as the Warburg effect), even in the presence of oxygen, leading to lactate production. Acidification is thought to promote invasion, metastasis, and resistance to certain chemotherapies. The body maintains a relatively stable pH in the blood (around 7.4). However, the pH of tissues can vary, and tumors can exhibit a lower pH. -Normal tissues have a higher extracellular pH than intracellular pH, in cancer is exactly the opposite. (inversion of the pH gradient). Cancer cells often overexpress proton pumps (such as V-ATPase) and transporters that actively extrude protons (H⁺) to maintain an intracellular pH conducive to their growth. Inhibiting these pumps can lead to intracellular acidification and potentially induce apoptosis or render cancer cells more vulnerable to other treatments. Normal pH levels in the body: Nasal: ~6.3 pH Mouth/saliva: 6.2-7.6 pH Stomach: 1-3 pH Small Intestine: 5.9-6.8 pH Colon/Large Intestine: 6.8-7 pH |
| - | in-vitro, | BC, | MCF-7 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:210 Target#:250 State#:% Dir#:4
wNotes=0 sortOrder:rid,rpid